Capecitabine is a prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. The activation of capecitabine follows a pathway with three enzymatic steps and two intermediary metabolites, 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouridine (5'-DFUR), to form 5-fluorouracil.
|In vitro||DMSO||72 mg/mL (200.36 mM)|
|Water||6 mg/mL (16.69 mM)|
|Ethanol||72 mg/mL (200.36 mM)|
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||27.82 mL||139.12 mL||278.24 mL|
|0.5 mM||5.56 mL||27.82 mL||55.65 mL|
|1 mM||2.78 mL||13.91 mL||27.82 mL|
|5 mM||0.56 mL||2.78 mL||5.56 mL|
*The above data is based on the productmolecular weight 359.4 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|MECHANISM OF ACTION||N/A|
|Storage||at -20°C 3 years Powder|